Granted Patent
B2
US 10,617,696 · App. 15/381,430 · Granted Apr 14, 2020
Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Assignee:
Clarus Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.
Claims (6)
1. An oral composition comprising a capsule and a liquid or semi-solid pharmaceutical formulation within the capsule, wherein the pharmaceutical formulation comprises:
19.8 percent by weight of testosterone undecanoate;
51.6 percent by weight of oleic acid;
16.1 percent by weight of polyoxyethylene (40) hydrogenated castor oil;
10 percent by weight of borage seed oil; and
2.5 percent by weight of peppermint oil.
Assignments (4)
RELEASE OF SECURITY INTEREST
Recorded Dec 6, 2022
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION
To: CLARUS THERAPEUTICS, INC.
Reel/Frame 062000/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 15, 2022
From: CLARUS THERAPEUTICS, INC.
To: TOLMAR, INC.
Reel/Frame 061774/0516 →
SECURITY INTEREST
Recorded Mar 12, 2020
From: CLARUS THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 052099/0349 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 12, 2017
From: DUDLEY, ROBERT E; CONSTANTINIDES, PANAYIOTIS P
To: CLARUS THERAPEUTICS, INC.
Reel/Frame 040958/0709 →
Continuity (4)
Cited By (1)